Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas
Jazyk angličtina Země Japonsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
26261072
DOI
10.1007/s12185-015-1847-4
PII: 10.1007/s12185-015-1847-4
Knihovny.cz E-zdroje
- Klíčová slova
- Lymphoma, PU.1, Prognosis, microRNA miR-155,
- MeSH
- antigeny CD38 metabolismus MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfom metabolismus mortalita MeSH
- mikro RNA biosyntéza MeSH
- nádorové biomarkery biosyntéza MeSH
- prevalence MeSH
- protein-tyrosinkináza ZAP-70 metabolismus MeSH
- protoonkogenní proteiny biosyntéza MeSH
- regulace genové exprese u nádorů * MeSH
- RNA nádorová biosyntéza MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- trans-aktivátory biosyntéza MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antigeny CD38 MeSH
- mikro RNA MeSH
- MIRN155 microRNA, human MeSH Prohlížeč
- nádorové biomarkery MeSH
- protein-tyrosinkináza ZAP-70 MeSH
- proto-oncogene protein Spi-1 MeSH Prohlížeč
- protoonkogenní proteiny MeSH
- RNA nádorová MeSH
- trans-aktivátory MeSH
- ZAP70 protein, human MeSH Prohlížeč
The transcription factor PU.1 and its inhibitory microRNA-155 (miR-155) are important regulators of B-cell differentiation. PU.1 downregulation coupled with oncogenic miR-155 upregulation has been reported in lymphoid malignancies; however, these data have not been studied across different subtypes in relation to clinical outcomes. We studied expression of miR-155 and PU.1 in the six most prevalent human B-cell lymphomas (n = 131) including aggressive (DLBCL, HL, MCL) and indolent (B-CLL/SLL, MZL, FL) types. Levels of miR-155 and PU.1 inversely correlated in DLBCL, B-CLL/SLL, and FL tumor tissues. In HL tissues, an exceptionally high level of miR-155 was found in patients with unfavorable responses to first-line therapy and those who had shorter survival times. PU.1 downregulation was noted in B-CLL/SLL samples positive for the adverse prognostic markers CD38 and ZAP-70. Upregulation of miR-155 and downregulation of PU.1 expression are integral aspects of lymphoma biology that could mark aggressive behavior of some, but not all, lymphoma types.
Zobrazit více v PubMed
Exp Hematol. 2007 Jul;35(7):1056-68 PubMed
Nature. 2010 Aug 12;466(7308):835-40 PubMed
Curr Opin Hematol. 2011 Jul;18(4):266-72 PubMed
Mol Cell Proteomics. 2012 May;11(5):77-89 PubMed
Blood. 2013 Sep 12;122(11):1891-9 PubMed
Immunity. 2007 Dec;27(6):847-59 PubMed
J Intern Med. 2008 Apr;263(4):366-75 PubMed
Blood. 2010 Apr 1;115(13):2630-9 PubMed
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 PubMed
Blood. 2011 Mar 10;117(10):2827-38 PubMed
Cancer. 2007 Jun 15;109(12):2473-80 PubMed
Methods. 2001 Dec;25(4):402-8 PubMed
Blood. 2005 Sep 15;106(6):2083-90 PubMed
Immunity. 1998 Apr;8(4):509-16 PubMed
Blood. 2011 Apr 7;117(14):3816-25 PubMed
J Pathol. 2005 Oct;207(2):243-9 PubMed
Blood. 2013 Feb 7;121(6):962-70 PubMed
J Exp Med. 2014 Oct 20;211(11):2183-98 PubMed
Leukemia. 2005 May;19(5):750-8 PubMed
Blood Cells Mol Dis. 2003 Sep-Oct;31(2):229-33 PubMed
Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):E1695-704 PubMed
J Pathol. 2006 Jul;209(3):352-9 PubMed
Int J Cancer. 2007 Sep 1;121(5):1156-61 PubMed
Neoplasia. 2009 Feb;11(2):167-76 PubMed
Haematologica. 2002 Oct;87(10):1021-7 PubMed
J Biol Chem. 1998 May 29;273(22):13375-8 PubMed
Leukemia. 2003 Dec;17(12):2426-34 PubMed
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 PubMed
